CDK inhibitors in hormone receptor positive advanced breast cancer

Authors : Bilge AKTAS

Pages : 35-39

Doi:10.5472/mmj.77406

View : 7 | Download : 10

Publication Date : 2015-09-30

Article Type : Research Paper

Abstract :Endocrine treatment is the current first line treatment in ER+ advanced breast cancer with a requirement of predictive biomarkers to the treatment and different approaches for endocrine resistance risk. Cyclin dependent kinases insert ignore into journalissuearticles values(CDKs); are regulating each step of cellular division in mammalian cell cycle and are hyperactivated in cancer cells causing cancer progression. Next generation pan-CDK inhibitors are in clinical development, while clinical trials in breast cancer, particularly in ER+ subtype where the greatest growth inhibition has been observed. Here I will review the data from this new class of drugs. Keywords: CDK inhibitors, Hormone positive advanced breast cancer, Targeted therapies, Palbociclib, Endocrine therapy resistance
Keywords : CDK inhibitors, Hormone positive advanced breast cancer, Targeted therapies, Palbociclib, Endocrine therapy resistance